Working capital per share of Alector, Inc. – GETTEX:0Z2
This page provides financial data, specifically working capital per share, for Alector, Inc. (0Z2) on the Gettex exchange. It appears to be a financial data portal displaying key metrics for interested investors. The data listed for "Period Value Change Change %" is currently empty.
Alector (ALEC) Surges 19.8% in Intraday Trading: Is This a Breakout or a Fleeting Spike?
Alector (ALEC) shares surged 19.8% in intraday trading on April 1, 2026, reaching $2.575, driven by short-term technical momentum and speculative options positioning. High volume in April 17 call options at the $2.5 strike suggests traders are anticipating a continued rally. While technical indicators show bullish signs, historical backtesting of similar surges yielded mixed long-term results, leading investors to question if this is a true breakout or a temporary spike.
12 Health Care Stocks Moving In Wednesday's Intraday Session
This article identifies several healthcare stocks that experienced significant intraday movement on Wednesday, listing both gainers and losers. Cyclerion Therapeutics and Axe Compute saw substantial increases, while ORIC Pharmaceuticals and Bristol-Myers Squibb Company Celegne Contingent Value Rights were among those that declined. The movements are attributed to various factors including recent earnings reports.
Alector (ALEC)'s technical outlook is bright after key golden cross
This article analyzes Alector (ALEC) stock's recent technical performance, highlighting a "golden cross" event where its 50-day moving average surpassed its 200-day moving average. This technical indicator suggests a potentially strong short-to-medium-term upward trend for the stock, making it an attractive prospect for investors.
Alector (ALEC) price target increased by 37.14% to 2.94
This article reports a significant increase in the price target for Alector (ALEC) stock. The target has been raised by 37.14% to $2.94. This adjustment could indicate a more optimistic outlook on the company's future performance by analysts.
Alector (ALEC) price target increased by 37.14% to 2.94
Alector (ALEC) has received a price target increase of 37.14%, raising it to $2.94. This suggests a positive reevaluation of the company's stock outlook by analysts.
HC Wainwright & Co. Maintains Alector (ALEC) Buy Recommendation
HC Wainwright & Co. has reiterated a Buy rating for Alector (ALEC) and set a price target of $17.00. This analyst action reflects continued confidence in the biotechnology company. Additional details regarding the basis for the rating and target would be provided in the full report.
Alector Inc. (ALEC) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Alector Inc. (ALEC) stock, showing its current price as $2.02, up 1.00%. It also includes sections for analyst ratings, noting zero ratings in the last three months, and states that earnings information is not currently available. The page heavily promotes signing up for free trade alerts and other trading resources.
Vanguard disaggregates holdings; reports 0% in Alector (ALEC)
Vanguard has filed an amended Schedule 13G/A, reporting 0% beneficial ownership in Alector (ALEC) common stock as of March 13, 2026. This change is due to an internal realignment on January 12, 2026, which led to certain Vanguard subsidiaries reporting their holdings separately. The filing clarifies that Vanguard no longer beneficially owns securities held by these disaggregated entities, indicating an administrative ownership clarification rather than a market transaction.
ALECTOR PB Ratio: 7.61 — 102% Above Median
Alector Inc (ALEC) currently has a Price-to-Book (PB) Ratio of 7.25 as of March 27, 2026, which is 92% above its 10-year median of 3.77. GuruFocus has rated ALEC with a GF Score™ of 37/100 and a GF Value™ of $0.85, indicating it is significantly overvalued at its current share price of $2.02. Alector's PB Ratio ranks worse than 79.68% of 1,240 Biotechnology companies, and it comes with 7 warning signs for investors.
If You Invested $1,000 in Alector (ALEC)
This article details the historical performance of investing $1,000 in Alector (ALEC) over various timeframes, showing significant losses over 5 and 10 years, despite a recent gain in the last year. It also provides an in-depth company profile of Alector, highlighting its focus on neurodegenerative diseases, its Alector Brain Carrier (ABC) platform, key clinical programs, and corporate developments including workforce reductions. The article includes frequently asked questions about the company's operations, clinical trials, and financial reporting.
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Alector (ALEC) reported a narrower-than-expected loss in Q2, while its revenues surpassed estimates. The company's net loss decreased from the prior-year quarter, and revenues also saw a significant increase. Management reiterated their financial guidance for the full year.
ALEC SEC Filings - Alector 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Alector's (ALEC) SEC filings, including 10-K, 10-Q, and 8-K reports, offering detailed insights into the biotechnology company's clinical progress, financial performance, and corporate activities. It highlights the use of AI-powered summaries to quickly extract key information from these documents and facilitates tracking of insider transactions via Form 4 filings. Recent Form 4 and Form 144 filings show sales of ALEC shares by directors and officers to cover tax obligations from RSU vesting.
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Alector (ALEC) reported a narrower-than-expected loss in the second quarter, coming in at a loss of $0.62 per share, which was better than the Zacks Consensus Estimate of a $0.72 loss. The company also surpassed revenue expectations, with sales reaching $23.2 million against an estimate of $13.62 million. However, the reported revenue was lower than the $42.2 million generated in the same quarter last year.
Alector, Inc. (NASDAQ:ALEC) Given Average Rating of "Hold" by Brokerages
Eight brokerages have given Alector, Inc. (NASDAQ:ALEC) an average rating of "Hold," with two issuing sell recommendations, four hold recommendations, and two buy recommendations. The average twelve-month price target for the stock is $4.1667. Several institutional investors have adjusted their positions in Alector, with Vanguard Group Inc. increasing its stake and new stakes purchased by Foresite Capital Management IV LLC and Balyasny Asset Management L.P. The company recently reported better-than-expected quarterly earnings, with an EPS of ($0.34) against an estimated ($0.39) and revenue of $6.24 million, exceeding the $1.78 million consensus.
Alector (ALEC) CEO awarded 116,246 RSUs, boosts direct share stake
Alector, Inc. CEO Arnon Rosenthal was granted 116,246 restricted stock units (RSUs) on March 13, 2026, as equity compensation. These RSUs, which have no cash cost, will vest in two equal installments on September 1, 2026, and March 1, 2027. This grant increases his direct ownership to 2,454,422 common shares, in addition to indirect holdings through family trusts.
Alector (ALEC) CFO granted 54,600 RSUs, holdings rise to 399,260 shares
Alector, Inc.'s CFO and Chief Business Officer, Neil Lindsay Berkley, was granted 54,600 restricted stock units (RSUs) as an equity award, increasing his total direct holdings to 399,260 shares. These RSUs will vest in two equal halves on September 1, 2026, and March 1, 2027, subject to continued service. This transaction was an equity grant, not an open-market purchase or sale.
Alector (ALEC) officer sells 1,000 shares under 10b5-1 plan
Alector, Inc.'s principal accounting officer, Grace Wong-Sarad, reported an open-market sale of 1,000 shares of common stock at $2.65 per share on March 10, 2026. This transaction was conducted under a pre-scheduled Rule 10b5-1 trading plan adopted on September 5, 2025. Following the sale, Wong-Sarad directly holds 106,465 shares of the company.
Insider Sell Alert: Grace Wong-sarad Sells Shares of Alector Inc (ALEC)
Grace Wong-sarad, Principal Accounting Officer at Alector Inc (ALEC), sold 1,000 shares of the company on March 10, 2026, reducing her holdings to 106,465 shares. This transaction is part of a pattern of insider selling, with 19 insider sells and no buys over the past year. Alector Inc, a biotechnology company focused on neurodegenerative diseases, is considered significantly overvalued based on its GF Value of $0.84 compared to its trading price of $2.65.
Alector Inc (ALEC) Stock News & Articles
This article provides an overview of Alector Inc. (ALEC), a biopharmaceutical company focused on neurodegenerative diseases, highlighting its stock data, key products (AL001 and AL101), and collaborations. It also features a recent article from March 10, 2026, by Joel South, noting that Wall Street analysts are turning bullish on ALEC due to strategic partnerships. The content emphasizes Alector's commitment to developing innovative therapies by activating the brain's immune system.
Alector stock rating upgraded to Buy at BTIG on BBB-shuttle focus
BTIG has upgraded Alector Inc. (NASDAQ:ALEC) to a Buy rating from Neutral, setting a price target of $6.00. This upgrade is driven by Alector's strategic shift to developing therapeutics utilizing blood-brain barrier shuttle domains, a move that BTIG believes positions the company to become a major player in neurodegeneration. Analysts expect Alector's lead programs for Alzheimer's and Parkinson's diseases to enter clinic in 2026, with potential for partnerships in the next 12-18 months.
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
A Benzinga article details five significant analyst upgrades for various companies on Tuesday, March 10, 2026. Notably, a Morgan Stanley analyst turned bullish on CrowdStrike Holdings, upgrading its rating and raising the price target. Other companies receiving upgrades include Alector Inc., Rivian Automotive Inc., Solaredge Technologies Inc., and Dianthus Therapeutics Inc., with analysts at BTIG, TD Cowen, B of A Securities, and Raymond James revising their outlooks and price targets.
Alector stock rating upgraded to Buy at BTIG on BBB-shuttle focus
BTIG has upgraded Alector Inc. (NASDAQ:ALEC) to a Buy rating from Neutral with a $6.00 price target, citing the company's strategic pivot towards developing therapeutics using blood-brain barrier shuttle domains. This shift removes uncertainty following a past trial failure and positions Alector to become a significant player in neurodegeneration, with lead programs in Alzheimer's and Parkinson's diseases expected to enter the clinic in 2026. BTIG anticipates Alector will partner specific shuttled programs within 12 to 18 months, leveraging its expertise in protein engineering and molecular mechanisms of neurodegeneration.
Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross
Alector, Inc. (ALEC) has shown a bright technical outlook after experiencing a "golden cross" event, where its 50-day simple moving average surpassed its 200-day simple moving average, signaling a potential bullish breakout. This technical indicator, combined with positive earnings outlook and recent stock movement, suggests further gains could be ahead for ALEC. Investors are advised to monitor ALEC for continued upward momentum.
Alector stock rating upgraded to Buy at BTIG on BBB-shuttle focus
BTIG has upgraded Alector Inc. (NASDAQ:ALEC) from Neutral to Buy, setting a price target of $6.00, significantly higher than its current trading price of $2.19. This upgrade is driven by Alector's strategic pivot towards developing therapeutics using blood-brain barrier shuttle domains, a move BTIG believes positions the company as a key player in neurodegeneration. Analysts anticipate Alector will engage in partnerships for specific shuttled programs within 12 to 18 months, leveraging its expertise in protein engineering and neurodegeneration molecular mechanisms.
Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross
Alector, Inc. (ALEC) has shown a positive technical outlook with its 50-day simple moving average crossing above its 200-day simple moving average, forming a "golden cross." This event, combined with positive earnings estimate revisions and a Zacks Rank of #3 (Hold), suggests potential for further stock gains. The company's stock has already risen 11.7% over the last four weeks.
RSU tax sale: Alector (NASDAQ: ALEC) CEO sells 81,864 shares
Alector, Inc.'s CEO, Arnon Rosenthal, sold 81,864 shares of common stock on March 2, 2026, at a weighted average price of $2.1233 per share. This sale was conducted to cover tax obligations arising from the vesting of restricted stock units (RSUs). Following this transaction, Rosenthal directly holds 2,338,176 shares and has significant indirect holdings through various family trusts.
Alector (ALEC) accounting chief sells 3,367 shares under 10b5-1 plan
Alector, Inc.'s Principal Accounting Officer, Grace Wong-Sarad, sold 3,367 shares of common stock on March 3, 2026, at a weighted average price of $2.0826 per share. This transaction was executed under a pre-established Rule 10b5-1 trading plan adopted in September 2025. Following the sale, Ms. Wong-Sarad directly owns 107,465 shares of Alector common stock.
Alector (NASDAQ:ALEC) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded Alector (NASDAQ:ALEC) from a "hold" to a "sell" rating, contributing to mixed analyst coverage with a consensus "Hold" rating and a $3.25 price target. Despite beating quarterly EPS and revenue estimates, Alector remains unprofitable with negative return on equity and projected negative EPS for the year. Insider selling has increased, though institutional investors hold a significant majority of the company's stock.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Xenon (XENE), Alector (ALEC) and Caris Life Sciences, Inc. (CAI)
This article examines analyst sentiments for three healthcare companies: Xenon (XENE), Alector (ALEC), and Caris Life Sciences, Inc. (CAI). Xenon received a "Strong Buy" consensus with a significant upside, Alector was rated "Hold" with a slight downside, and Caris Life Sciences, Inc. also garnered a "Strong Buy" with a substantial upside despite one analyst maintaining a "Hold" rating. The report highlights individual analyst ratings, price targets, and their success rates according to TipRanks.
ALEC Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for ALEC, including past quarterly results and future forecasts. It details revenue and EPS figures, analyst estimates, and how stock price movements correlate with earnings revisions. The piece also discusses historical stock reactions to earnings reports and key insights from an earnings call summary.
Neil Berkley sale 37,261 shares; ALEC (NASDAQ: ALEC) RSUs vest 45,520
Alector, Inc. (NASDAQ: ALEC) reported insider transaction activity via a Form 144 filing. The filing indicates that Neil Berkley sold 37,261 shares on December 3, 2025, and also notes the vesting of 45,520 restricted stock units on February 27, 2026. The document also details an outstanding share figure of 110,374,418 shares as of March 2, 2026.
[144] Alector, Inc. SEC Filing
This SEC Form 144 filing for Alector, Inc. (ALEC) details planned and recent sales of restricted common stock. It lists planned sales of 347 shares on March 1, 2025, and 3,732 shares on June 1, 2025, along with recent sales by Grace Wong-Sarad of 4,753 shares on December 5, 2025, and 8,056 shares on December 3, 2025. The filing reflects routine attestations required under resale rules and has a neutral impact and sentiment according to Rhea-AI.
Alector (ALEC) Posts Steep US$37 Million Quarterly Loss Testing Bullish Pipeline Narratives
Alector (ALEC) reported a significant Q4 FY 2025 loss of US$37.3 million, with a net loss of US$142.9 million for the full year, despite quarterly revenues ranging from US$3.3 million to US$7.9 million. The company's shares trade at a premium 13.3x P/S multiple while remaining unprofitable, sparking skepticism despite bullish narratives about its neurodegeneration pipeline. Analysts anticipate Alector will remain unprofitable for at least the next three years, highlighting a mismatch between its valuation and current financial performance.
Alector (NASDAQ:ALEC) Insider Grace Wong-Sarad Sells 4,079 Shares
Alector (NASDAQ:ALEC) insider Grace Wong-Sarad sold 4,079 shares of the company's stock on February 26th at an average price of $2.50, reducing her stake by 3.32%. This sale follows recent positive news for Alector, including a Q4 earnings beat and significant call-option buying, which saw the stock jump 7.1%. The company currently holds a consensus "Hold" rating from analysts with an average target price of $3.25.
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Alector, Inc. reported its fourth quarter and full year 2025 financial results, highlighting a cash position of $256.0 million, expected to fund operations through 2027. The company is advancing its Alector Brain Carrier (ABC) platform with multiple therapeutic modalities and anticipates an independent interim futility analysis for its PROGRESS-AD Phase 2 trial of nivisnebart in early Alzheimer’s disease in the first half of 2026. Alector also provided updates on its preclinical programs, including AL137 for Alzheimer's and AL050 for Parkinson's, and its ABC-enabled siRNA platform.
Alector earnings beat by $0.05, revenue topped estimates
Alector (NASDAQ: ALEC) reported fourth-quarter EPS of $-0.34, beating analyst estimates by $0.05, and revenue of $6.2M, exceeding the consensus of $2.38M. The company's stock has shown significant gains over the last 3 and 12 months, and InvestingPro indicates a "fair performance" financial health score.
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Alector, Inc. announced its financial results for the fourth quarter and full year 2025, reporting $256.0 million in cash, cash equivalents, and investments, projected to fund operations through 2027. The company is advancing its Alector Brain Carrier (ABC) platform with therapeutic candidates for Alzheimer's and Parkinson's diseases, including AL137, AL050, and AL064, and anticipates an interim futility analysis for the PROGRESS-AD Phase 2 trial of nivisnebart in early Alzheimer’s disease in the first half of 2026.
Alector (Nasdaq: ALEC) 2025 revenue drops as R&D falls and cash tops $256M
Alector (ALEC) reported a significant drop in collaboration revenue in 2025 to $21.0 million from $100.6 million in 2024, primarily due to the completion of prior collaboration milestones. Despite reducing R&D and G&A expenses, the net loss widened to $142.9 million. The company ended 2025 with $256.0 million in cash, which is expected to fund operations through at least 2027, as it continues to advance its neurodegeneration pipeline including AL137, AL050, AL064, and the PROGRESS-AD Phase 2 trial of nivisnebart.
Alector: Q4 Earnings Snapshot
Alector Inc. (ALEC) reported a Q4 loss of $37.3 million, or 34 cents per share, which surpassed Wall Street expectations. The biotechnology company also exceeded revenue forecasts, posting $6.2 million for the period. Despite widening losses for the full year, the company's shares traded higher than the previous year.
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
Alector, Inc. (Nasdaq: ALEC) announced that its management will participate in a corporate presentation at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 pm ET. The clinical-stage biotechnology company focuses on developing therapies for neurodegenerative diseases and will provide a live webcast of the presentation. A replay will be available for 90 days on the "Events & Presentations" section of their website.
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company, announced its management will participate in a corporate presentation at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 pm ET. A live webcast and replay of the presentation will be available on the Investors section of Alector’s website. The company focuses on developing therapies for neurodegenerative diseases and is also advancing its proprietary Alector Brain Carrier (ABC) platform.
Alector (NASDAQ:ALEC) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Alector (NASDAQ:ALEC) from a "sell" to a "hold" rating, contributing to a mixed analyst sentiment with a consensus "Hold" rating and an average price target of $3.25. The article highlights recent insider stock sales totaling around $220,064 and details the company's financial metrics and institutional ownership. Alector, a clinical-stage biotechnology company, focuses on developing immuno-neurology therapies for neurodegenerative disorders like Alzheimer's and frontotemporal dementia.
Alector, Inc. (NASDAQ:ALEC) Receives Average Recommendation of "Hold" from Brokerages
Alector, Inc. (NASDAQ:ALEC) has received an average "Hold" recommendation from eight brokerage firms, with a 12-month average price target of $3.25. Insiders have recently sold approximately 196,104 shares, including CEO Arnon Rosenthal, though institutional ownership remains high at 85.83%. The company, a clinical-stage biotechnology firm focused on neurodegenerative disorders, currently trades around $1.98 with a market capitalization of $216 million.
ALEC: Sector Tailwinds And Deal Optionality Will Shape Measured Future Upside
Analysts have slightly increased their consensus price target for Alector (ALEC) from US$0.75 to US$0.90, attributing it to potential tailwinds for U.S. small and mid-cap biotech firms as larger pharmaceutical companies face a patent cliff. While maintaining an "Underweight" rating, the updated outlook suggests a balance between acknowledging broader sector opportunities and lingering concerns about Alector's specific execution and fundamentals. Recent news includes Alector's removal from the NASDAQ Biotechnology Index and the appointment of Neil Berkley as CFO, effective December 10, 2025.
Legal Scrutiny Adds to Alector’s Clinical Setback Challenges
Alector Inc. is facing significant challenges, including a legal investigation by Levi & Korsinsky, following the failure of its INFRONT-3 Phase 3 clinical trial for latozinemab. The company is restructuring its executive team and shifting its strategic focus to nivisnebart, a drug candidate for Alzheimer's disease, with an interim analysis expected in the first half of 2026. Vanguard Group maintains a substantial stake in Alector, indicating continued investor interest despite the setbacks.
INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint
Levi & Korsinsky, LLP is investigating Alector, Inc. (NASDAQ: ALEC) following the announcement that its Phase 3 INFRONT-3 trial for latozinemab failed to meet its clinical co-primary endpoint for slowing progression in frontotemporal dementia. The trial met its biomarker response endpoint but missed the clinical response endpoint, leading analysts to downgrade the stock. The law firm is inviting investors with concerns to contact them for more information regarding Alector's operational performance.
There's No Escaping Alector, Inc.'s (NASDAQ:ALEC) Muted Revenues Despite A 32% Share Price Rise
Alector, Inc.'s stock has seen a 32% rise recently, but its muted revenue growth and a low price-to-sales (P/S) ratio of 3x suggest underlying issues. Analysts forecast a 50% annual revenue contraction over the next three years, contrasting sharply with the broader biotech industry's expected 126% growth. This weak outlook justifies Alector's low P/S ratio and could hinder long-term share price stability.
Levi & Korsinsky Announces an Investigation on Behalf of Alector, Inc. (ALEC) Shareholders Who May Have Been Affected by Fraud
Levi & Korsinsky has initiated an investigation into Alector, Inc. (ALEC) concerning potential violations of federal securities laws. This follows Alector's announcement on October 22, 2025, that its Phase 2 clinical trial for latozinemab in frontotemporal dementia did not show a clinical benefit, causing ALEC's stock to drop over 52%. The firm is inviting affected shareholders to seek additional information regarding a possible class-action lawsuit.
Alector, Inc. (NASDAQ:ALEC) Given Average Rating of "Reduce" by Analysts
Nine analysts have given Alector, Inc. (NASDAQ:ALEC) an average rating of "Reduce," with a 12-month average target price of $3.25. The company currently trades around $1.52, has a market cap of $165.9 million, and reported an EPS of ($0.34) for the last quarter. Significant insider selling, including by the CEO, occurred in December, and institutional investors hold approximately 85.8% of the stock.
